Special Issue "Histone Deacetylase Inhibitors in Health and Disease"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 January 2019).
Interests: biochemistry of carcinogenesis; xenobiochemistry; anticancer drugs; DNA-damaging drugs; epigenetic regulation; drug metabolism; drug targeting
Interests: neuroinflammation; epigenetic regulations; microglia; inflammatory mediators; pharmacology
Alteration of the histone proteins associated with DNA is a crucial process in the epigenetic regulation of DNA structure and function. Such epigenetic modifications, which play a fundamental role in human development, are also relevant for the initiation and progression of complex degenerative diseases and cancer. Histone deacetylases (HDACs) catalyze deacetylation of lysine residues leading to changes in expression of genes encoded by DNA linked to the histone molecule. HDAC inhibitors (HDACi) that consecutively regulate the activity of HDACs, have been extensively researched as therapeutics in psychiatry and neurology, in which a number of adverse outcomes are associated with aberrant HDAC function. Furthermore, HDACi have shown potential for the treatment of cardiac, neurodegenerative and inflammatory lung diseases. On the other hand, increased HDAC activity and expression was found in the development of different cancers, HDACi have also been shown to serve in, and have been approved for, potential cancer treatments, either on their own or in combination with other therapies, such as chemotherapy drugs. The mechanisms of action of HDAC inhibitors are based on changed gene expression and on alterations of histone or non-histone protein molecules through modulation of epigenetic and post-translational modifications, respectively. The shift to an enhanced acetylation/deacetylation status in a variety of tumors due to HDAC inhibition can result in modified gene expression, alteration of cell signaling processes, and can influence the proteasome system, activities of some protein kinases, as well as DNA demethylation. As a result, several biological processes, such as cell cycle arrest or apoptosis, are modified. In addition, HDAC inhibitors have antiangiogenic effects or can influence some cell signaling pathways, having a wide spectrum of effects. These findings indicate that HDACi play a crucial role, both in physiological development and the progression of many human diseases.
In this context, we would like to invite review and original articles that focus on understanding HDACi function in health and disease, especially in human cancer. In addition, articles associated with model disease systems, drug resistance, and therapy are requested for this Special Issue.
Prof. Dr. Marie Stiborova
Prof. Dr. George Hsiao
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Epigenetic regulations
- Histone modifications
- Deacetylases of histone lysines
- Histone deacetylases as chromatin modifying enzymes
- Histone deacetylase inhibitors
- Role of histone deacetylase inhibitors in cancer, neurological diseases and immune disorders
- Histone deacetylase inhibitors in human therapy